Related Experiment Video
Updated: Apr 28, 2026

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation
Hoang M Lai1, Rahul Pawar, David C Wolf
11Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY; and 2Division of Gastroenterology and Hepatobiliary Disease, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.
Insights
Liver transplant recipients frequently develop cardiovascular risks like hypertension and diabetes. Post-transplant, diabetes mellitus and hepatitis C significantly increase mortality, while hypercholesterolemia may be protective.
Area of Science:
- Hepatology
- Transplantation Medicine
- Cardiovascular Medicine
Background:
- Calcineurin inhibitor immunosuppression post-liver transplant is linked to increased cardiovascular risk factors.
- Hypertension, diabetes, and hypercholesterolemia are common complications in liver transplant recipients.
Purpose of the Study:
- To assess the prevalence of cardiovascular risk factors after liver transplantation.
- To evaluate the management of these risk factors and their impact on long-term mortality.
- To identify pre- and post-transplant predictors of mortality.
Main Methods:
- Retrospective review of medical records for 333 adult liver transplant recipients.
- Data collection included pre- and post-transplant diagnoses, medication use, and mortality.
- Statistical analysis, including stepwise logistic regression, identified mortality risk factors.
Main Results:
- High post-transplant prevalence: hypertension (67%), chronic kidney disease (45%), diabetes mellitus (42%), hypercholesterolemia (46%).
- Mortality was 29% over a mean follow-up of 50 months.
- Independent mortality predictors: pre-transplant (age, hepatitis C), post-transplant (diabetes mellitus, cancer). Hypercholesterolemia was a negative predictor.
Conclusions:
- Cardiovascular risk factors are highly prevalent after liver transplantation.
- Diabetes mellitus and hepatitis C are significant contributors to post-transplant mortality.
- Certain immunosuppressants (tacrolimus, mycophenolate) may be associated with better survival outcomes.
Abstract:
Immunosuppression with calcineurin inhibitors has contributed to an increased prevalence of hypertension, diabetes, and hypercholesterolemia in patients receiving liver transplantation. This study evaluated the prevalence of cardiovascular risk factors, their management, and long-term mortality after liver transplantation. Medical records were reviewed in 333 adult patients who underwent orthotopic liver transplantation. Data were collected on medical diagnoses before and after transplantation, medication use, and on long-term mortality. The 333 patients in the study included 223 men and 110 women, mean age 59 ± 10 years. The mean follow-up was 50 ± 28 months. After transplantation, there was a high prevalence of hypertension (67%), hypercholesterolemia (46%), diabetes mellitus (42%), and chronic kidney disease (45%). Out of 333 patients in the study, 96 patients (29%) died during follow-up. Stepwise logistic regression was performed to identify the risk factors that might influence long-term mortality outcomes. Based on pretransplant characteristics, positive independent risk factors that increased mortality were age at transplant and hepatitis C. After transplantation, positive predictive factors were diabetes mellitus and cancer. A negative predictive risk factor for mortality was hypercholesterolemia. Analysis of medication after transplantation showed that positive predictive factors were the use of insulin, steroids, and antibiotics. Negative predictors for mortality were tacrolimus and mycophenolate. Our data suggest that diabetes mellitus and hepatitis C play an important role in worsening posttransplant mortality.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

